Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
the internet as a source of information for patients with sarcoidosis
Original title: “[The internet as a source of information for patients with sarcoidosis].”
streptococcus intermedius cerebellar abscess as first presentation of sarcoidosis a case report
Original title: “Streptococcus intermedius cerebellar abscess as first presentation of sarcoidosis: a case report.”
targeting cxcr6 suppresses granuloma formation and pulmonary fibrosis through inhibiting th17 responses in sarcoidosis
Original title: “Targeting CXCR6 suppresses granuloma formation and pulmonary fibrosis through inhibiting Th17 responses in sarcoidosis.”
overlap syndrome between sarcoidosis and sj gren s disease presenting as hypopituitarism case report and review of literature
Original title: “Overlap syndrome between sarcoidosis and Sjögren's disease presenting as hypopituitarism: case report and review of literature.”
oral sarcoidosis a systematic review of dental implications
Original title: “Oral Sarcoidosis: A Systematic Review of Dental Implications.”
association of the tnfrsf1a genotype with lung function impairment in patients with sarcoidosis
Original title: “Association of the TNFRSF1A genotype with lung function impairment in patients with sarcoidosis.”
early calciphylaxis mimicking infection in a patient with end stage renal disease and sarcoidosis a diagnostic and wound management challenge
Original title: “Early Calciphylaxis Mimicking Infection in a Patient With End-Stage Renal Disease and Sarcoidosis: A Diagnostic and Wound Management Challenge.”
pediatric sarcoidosis with chronic massive splenomegaly and renal involvement a case report
Original title: “Pediatric Sarcoidosis With Chronic Massive Splenomegaly and Renal Involvement: A Case Report.”
bone sarcoidosis an underrecognized manifestation of a multisystemic disease
Original title: “[Bone sarcoidosis: an underrecognized manifestation of a multisystemic disease].”
advanced cardiac imaging in cardiac sarcoidosis current evidence and future directions
Original title: “Advanced cardiac imaging in cardiac sarcoidosis: current evidence and future directions.”
association of cardiac sarcoidosis with coronary slow flow a case report unraveling the enigma
Original title: “Association of cardiac sarcoidosis with coronary slow flow: a case report unraveling the enigma.”
diagnostic delay and phenotypic differences in cardiac sarcoidosis a descriptive study of diagnostic and follow up clinical data
Original title: “Diagnostic delay and phenotypic differences in cardiac sarcoidosis: a descriptive study of diagnostic and follow-up clinical data.”
CHICAGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) has been named a 2025 RareVoice Awards recipient by EveryLife Foundation for Rare Diseases, earning national recognition for Federal Advocacy by a Patient or Organization. Foundation for Sarcoidosis Research is proud to receive 2025 RareVoice Award for Federal Advocacy and attend Rare Disease Month on Capitol Hill... Awardees are selected from nominations submitted by patients, caregivers, advocates, and organizations across the rare disease community. “Advocacy means standing in the gap until systems change and patients are seen, heard, and served”, said Mary McGowan, President and CEO of FSR. As part of these efforts, Rare Disease Week on Capitol Hill will take place the last week of February, bringing together patients, caregivers, advocates, researchers, and policymakers from across the country. The 2025 RareVoice Awardees will be featured during Rare Disease Week on Capitol Hill, including at the RareVoice Success Panel, where awardees will share their advocacy journeys and policy impact. sarcoidosis rare disease february chronic illness award rare disease month advocacy fmla capitol hill GlobeNewswire · January 21, 2026 11:08 ET | Source: Foundation for Sarcoidosis Research
Original title: “Foundation for Sarcoidosis Research Receives 2025 RareVoice Award for Federal Advocacy During Rare Disease Month”
CHICAGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) has been named a 2025 RareVoice Awards recipient by EveryLife Foundation for Rare Diseases, earning national recognition for Federal Advocacy by a Patient or Organization. Foundation for Sarcoidosis Research is proud to receive 2025 RareVoice Award for Federal Advocacy and attend Rare Disease Month on Capitol Hill... Awardees are selected from nominations submitted by patients, caregivers, advocates, and organizations across the rare disease community. “Advocacy means standing in the gap until systems change and patients are seen, heard, and served”, said Mary McGowan, President and CEO of FSR. As part of these efforts, Rare Disease Week on Capitol Hill will take place the last week of February, bringing together patients, caregivers, advocates, researchers, and policymakers from across the country. The 2025 RareVoice Awardees will be featured during Rare Disease Week on Capitol Hill, including at the RareVoice Success Panel, where awardees will share their advocacy journeys and policy impact. sarcoidosis rare disease february chronic illness award rare disease month advocacy fmla capitol hill GlobeNewswire · January 21, 2026 11:08 ET | Source: Foundation for Sarcoidosis Research
Original title: “Foundation for Sarcoidosis Research Receives 2025 RareVoice Award for Federal Advocacy During Rare Disease Month”
intraosseous sarcoidosis imitating peri implantitis a case study
Original title: “Intraosseous sarcoidosis imitating peri-implantitis: A case study.”
According to Priovant, the Phase 2 BEACON study is the first industry-sponsored placebo-controlled trial in cutaneous sarcoidosis to deliver positive data.
Original title: “Priovant Plots Path to Phase 3 as Brepocitinib Clears Mid-Stage Skin Disease Study”
sarcoidosis disease mechanisms diagnostic pathway and treatment
Original title: “Sarcoidosis: Disease mechanisms, diagnostic pathway and treatment.”